Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | Anti-SLAMF7 CAR T cells |
Synonyms | |
Therapy Description |
Anti-SLAMF7 CAR T cells are T-cells that express a chimeric antigen receptor derived from the SLAMF7 (CS1)-targeting antibody elotuzumab, which potentially results in anti-tumor activity against SLAMF7-expressing tumor cells (PMID: 29089311). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
Anti-SLAMF7 CAR T cells | Autologous Anti-SLAMF7 CAR T-cells|SLAMF7 CAR-T cells | Anti-SLAMF7 CAR T cells are T-cells that express a chimeric antigen receptor derived from the SLAMF7 (CS1)-targeting antibody elotuzumab, which potentially results in anti-tumor activity against SLAMF7-expressing tumor cells (PMID: 29089311). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT04499339 | Phase Ib/II | Anti-SLAMF7 CAR T cells | A Phase I/IIa Clinical Trial to Assess Feasibility, Safety and Antitumor Activity of Autologous SLAMF7 CAR-T Cells in Multiple Myeloma | Active, not recruiting | FRA | ESP | DEU | 0 |